Efficacy of divalproex therapy for schizoaffective disorder

Ann M. Bogan, E. Sherwood Brown, Trisha Suppes

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Schizoaffective disorder is a common, severe, and lifelong illness; however, little is known about the pharmacologic treatment of this mental disorder. Divalproex has proven efficacy in the treatment of bipolar disorder. Therefore, to determine whether divalproex is also effective as adjunctive therapy for schizoaffective disorder, the authors performed a retrospective study of 20 patients in the public mental health system with schizoaffective disorder, bipolar type, who initiated divalproex therapy. The mean maximum dose of divalproex (±1 SD) was 1,150 mg (±400 mg; range, 500-2,000). The mean peak serum valproic acid level was 61 μg/mL (±25 μg/mL; range, 20-92). The overall improvement in Clinical Global Impression Scale scores was observed in 75% (15/20) of the patients (p = 0.0001). None in the sample worsened, and none discontinued divalproex because of side effects. These data suggest that divalproex is well-tolerated and effective as treatment of persistent schizoaffective disorder, bipolar type. Thus, divalproex may be an effective agent in the treatment of schizoaffective disorder as well as bipolar disorder. Controlled prospective trials in patients with schizoaffective disorder are needed to verify these findings.

Original languageEnglish (US)
Pages (from-to)520-522
Number of pages3
JournalJournal of Clinical Psychopharmacology
Volume20
Issue number5
DOIs
StatePublished - 2000

Fingerprint

Valproic Acid
Psychotic Disorders
Therapeutics
Bipolar Disorder
Mental Disorders
Mental Health
Retrospective Studies
Public Health
Serum

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Efficacy of divalproex therapy for schizoaffective disorder. / Bogan, Ann M.; Brown, E. Sherwood; Suppes, Trisha.

In: Journal of Clinical Psychopharmacology, Vol. 20, No. 5, 2000, p. 520-522.

Research output: Contribution to journalArticle

@article{7c6a011b1ce64c0fb3b2950d11b1a1c2,
title = "Efficacy of divalproex therapy for schizoaffective disorder",
abstract = "Schizoaffective disorder is a common, severe, and lifelong illness; however, little is known about the pharmacologic treatment of this mental disorder. Divalproex has proven efficacy in the treatment of bipolar disorder. Therefore, to determine whether divalproex is also effective as adjunctive therapy for schizoaffective disorder, the authors performed a retrospective study of 20 patients in the public mental health system with schizoaffective disorder, bipolar type, who initiated divalproex therapy. The mean maximum dose of divalproex (±1 SD) was 1,150 mg (±400 mg; range, 500-2,000). The mean peak serum valproic acid level was 61 μg/mL (±25 μg/mL; range, 20-92). The overall improvement in Clinical Global Impression Scale scores was observed in 75{\%} (15/20) of the patients (p = 0.0001). None in the sample worsened, and none discontinued divalproex because of side effects. These data suggest that divalproex is well-tolerated and effective as treatment of persistent schizoaffective disorder, bipolar type. Thus, divalproex may be an effective agent in the treatment of schizoaffective disorder as well as bipolar disorder. Controlled prospective trials in patients with schizoaffective disorder are needed to verify these findings.",
author = "Bogan, {Ann M.} and Brown, {E. Sherwood} and Trisha Suppes",
year = "2000",
doi = "10.1097/00004714-200010000-00004",
language = "English (US)",
volume = "20",
pages = "520--522",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Efficacy of divalproex therapy for schizoaffective disorder

AU - Bogan, Ann M.

AU - Brown, E. Sherwood

AU - Suppes, Trisha

PY - 2000

Y1 - 2000

N2 - Schizoaffective disorder is a common, severe, and lifelong illness; however, little is known about the pharmacologic treatment of this mental disorder. Divalproex has proven efficacy in the treatment of bipolar disorder. Therefore, to determine whether divalproex is also effective as adjunctive therapy for schizoaffective disorder, the authors performed a retrospective study of 20 patients in the public mental health system with schizoaffective disorder, bipolar type, who initiated divalproex therapy. The mean maximum dose of divalproex (±1 SD) was 1,150 mg (±400 mg; range, 500-2,000). The mean peak serum valproic acid level was 61 μg/mL (±25 μg/mL; range, 20-92). The overall improvement in Clinical Global Impression Scale scores was observed in 75% (15/20) of the patients (p = 0.0001). None in the sample worsened, and none discontinued divalproex because of side effects. These data suggest that divalproex is well-tolerated and effective as treatment of persistent schizoaffective disorder, bipolar type. Thus, divalproex may be an effective agent in the treatment of schizoaffective disorder as well as bipolar disorder. Controlled prospective trials in patients with schizoaffective disorder are needed to verify these findings.

AB - Schizoaffective disorder is a common, severe, and lifelong illness; however, little is known about the pharmacologic treatment of this mental disorder. Divalproex has proven efficacy in the treatment of bipolar disorder. Therefore, to determine whether divalproex is also effective as adjunctive therapy for schizoaffective disorder, the authors performed a retrospective study of 20 patients in the public mental health system with schizoaffective disorder, bipolar type, who initiated divalproex therapy. The mean maximum dose of divalproex (±1 SD) was 1,150 mg (±400 mg; range, 500-2,000). The mean peak serum valproic acid level was 61 μg/mL (±25 μg/mL; range, 20-92). The overall improvement in Clinical Global Impression Scale scores was observed in 75% (15/20) of the patients (p = 0.0001). None in the sample worsened, and none discontinued divalproex because of side effects. These data suggest that divalproex is well-tolerated and effective as treatment of persistent schizoaffective disorder, bipolar type. Thus, divalproex may be an effective agent in the treatment of schizoaffective disorder as well as bipolar disorder. Controlled prospective trials in patients with schizoaffective disorder are needed to verify these findings.

UR - http://www.scopus.com/inward/record.url?scp=0033825642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033825642&partnerID=8YFLogxK

U2 - 10.1097/00004714-200010000-00004

DO - 10.1097/00004714-200010000-00004

M3 - Article

VL - 20

SP - 520

EP - 522

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -